SomaLogic Announces Appointment of Steven Mermelstein as Senior Vice President of Corporate Strategy, Development and Mergers and Acquisitions
BOULDER, Colo., December 2, 2021 (GLOBE NEWSWIRE) – SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Steve Mermelstein has been appointed Senior Vice President of Corporate Strategy, Development and. The company has joined mergers and acquisitions (M&A).
“We are very excited to have Steve on the SomaLogic team,” said Roy Smythe, MD, SomaLogic’s chief executive officer. I look forward to working with Steve as we continue to scale our business rapidly. “
Steve has over 25 years of experience providing strategic and corporate finance advice to senior management teams and boards of directors. He has conducted a wide range of corporate transactions including M&A, growth equity investments, recapitalizations, out-licensing and joint ventures.
Previously, he was Vice President of Strategy and Corporate Development at Agilent Technologies, where he led the M&A, integration and market analysis teams. Prior to that, Steve served as Managing Director at Covington Associates, advising institutional and medium-sized companies in the life science sector. He was also a Managing Director at Huron Consulting Group, where he led the life sciences investment banking practice of Huron Transaction Advisory LLC. Before that, he was a Director at Wasserstein Perella & Co., where he was responsible for private equity and M&A advisory across all industries. Steve started his career at JPMorgan Chase & Co. where he specialized in M&A advisory and private equity investments through Chase Capital.
Steve received an AB in Government from Dartmouth College and an Executive MBA in Finance from New York University’s Stern School of Business. “I am very excited to be part of a great team at SomaLogic that is poised for significant further expansion in the dynamic and rapidly growing proteomics space,” he said.
The story goes on
SomaLogic (Nasdaq: SLGC) strives to provide accurate, meaningful, and actionable health management information that enables people worldwide to continuously optimize their personal health and well-being throughout their lives. This vital information, shared across a global network of partners and users, comes from SomaLogic’s personalized measurement of key changes in a person’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.
SomaSignal ™ tests are developed and determined by SomaLogic, Inc. for their performance characteristics. They have not been approved or approved by the U.S. Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited laboratory.
Disclaimer for forward-looking statements
This press release contains certain forward-looking statements within the meaning of U.S. securities laws with respect to the proposed business combination between SomaLogic and CM Life Sciences II and otherwise, including statements regarding the expected benefits of the business combination, the anticipated timing of the business combination, expansion plans, projected future results, and SomaLogic’s market opportunities. These forward-looking statements are generally identified by the words “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan,” ” can ”,“ should ”,“ will ”,“ would ”,“ will be ”,“ will go on ”,“ will likely result ”and similar expressions. Forward-looking statements are predictions, forecasts and other statements about future events that are based on current expectations and assumptions and are therefore subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors beyond the control of SomaLogic or CM Life Sciences II. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the CM Life Sciences II registry
Declaration on Form S-4 (File Number 333-256127) (the “Registration Declaration”) and the final proxy declaration / prospectus contained therein. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements only apply at the time of their publication. Readers are cautioned not to place undue reliance on forward-looking statements and SomaLogic and CM Life Sciences II undertake no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Neither SomaLogic nor CM Life Sciences II make any representation that either SomaLogic or CM Life Sciences II or the combined company will meet their expectations.
Lynn Lewis or Marissa Bych
Gilmartin Group LLC